Genetic Studies of Food Allergies Concept Award – The intent of this award mechanism is to support the exploration of a highly innovative new concept or untested theory that addresses an important problem relevant to the genetics of food allergies. Innovation and novelty of the concept are the most important aspects of this award mechanism. The Concept Award is not intended to support a logical progression of an already established research project, but instead, supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities. This may include high-risk, potentially high-gain approaches to genetic research focused on food allergies, provided that the scientific rationale supports the feasibility and development of the proposed concept. Research that is an incremental advance upon published data is not considered innovative and will not be considered for funding under this award mechanism. Total Funding: $790K. Eligibility: All. Pre-Application Due Date: May 27, 2010. Application Due Date: June 10, 2010.
Posted Date: March 23, 2010
Funding Opportunity Number: W81XWH-10-GSFARP-CA
————————————————————————————–
Genetic Studies of Food Allergies Idea Award – The Idea Award is designed to support innovative ideas and high-impact approaches relevant to the genetics of food allergies. This award mechanism is designed to support new ideas, not ideas that are extensions of existing work. Applications should have a high probability of revealing new avenues of investigation. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale. The GSFARP seeks applications from all areas of basic, preclinical, and epidemiological research. The following are significant features of this award mechanism: 1) Innovation; 2) Impact; and 3) Preliminary Date. Total Funding: $900K. Pre-Application Due Date: May 27, 2010. Application Due Date: June 10, 2010.
Posted Date: March 23, 2010
Funding Opportunity Number: W81XWH-10-GSFARP-IA
————————————————————————————–
Prostate Cancer Training Award – The Prostate Cancer Training Award supports predoctoral or postdoctoral training opportunities focused on prostate cancer research or patient care for individuals in the early stages of their careers. The trainee will be considered the Principal Investigator (PI) and author of the proposal. These awards primarily provide salary support for the PI and require the active involvement of a mentor who is an established prostate cancer researcher, as evidenced by a demonstrated record of funding and publications in prostate cancer research. The PCRP seeks applications from the wide spectrum of basic to clinical research, that are responsive to at least one of the PCRP focus areas. It is encouraged, although not required, that Prostate Cancer Training Award applications also be responsive to at least one of the PCRP overarching challenges. It is the responsibility of the PI to clearly and explicitly articulate how the project addresses the following important aspects of the Prostate Cancer Training Award: 1. Principal Investigator and Mentor: The PI must demonstrate strong qualifications for and a commitment to pursuing a career as a prostate cancer researcher or clinician. 2. Training Program and Environment: The PI must outline an individualized training program designed to prepare him/her for an independent career in prostate cancer research or patient care. An environment appropriate to the proposed training and research project must be clearly described. Total Award: $3.5M. Eligibility: All. Pre-application Due Date: May 5, 2010. Closing Date: May 26, 2010.
Posted Date: March 3, 2010
Funding Opportunity Number: W81XWH-10-PCRP-PCTA
————————————————————————————–
Prostate Cancer Physician Research Training Award – The Physician Research Training Award supports a mentored training experience to prepare physicians with clinical duties and/or responsibilities for productive careers in prostate cancer research. Applications must include a robust description of an individualized training program appropriate to the area of study, which may include coursework and seminars that will provide the Principal Investigator (PI) with experience in key areas such as statistics, bioethics, and/or relevant basic science disciplines. This award requires the involvement of a designated mentor with an established research program in prostate cancer. This award is intended to provide aggressive protection of at least 40% of the PI’s time for research. The PI must demonstrate a commitment to a career in prostate cancer research and clinical practice. In addition, salary for up to a 50% combined level of effort from one to two key support personnel may be provided by this award. Up to $10,000 in funds per year from this award may be used for research supplies and equipment. These funds may be used for research with laboratory animals and human biological substances, as well as research with human subjects, provided that the funds are not used to support clinical trials. PIs may participate in clinical trials as part of their training for this award, but funding for the clinical trials must come from a source other than this award. The PCRP seeks Physician Research Training Award applications from the wide spectrum of basic to clinical research, that are responsive to at least one of the PCRP focus areas. It is strongly encouraged, although not required, that applications also be responsive to at least one of the PCRP overarching challenges.
Posted Date: March 3, 2010
Funding Opportunity Number: W81XWH-10-PCRP-PRTA
————————————————————————————–
Neurofibromatosis Research Program (NFRP) Postdoctoral Traineeship Award (PTA) – The intent of the training award is to enable recent medical or other doctoral degree graduates to obtain the necessary experience to pursue an independent career in NF research. Candidates for this award should exhibit a strong desire to pursue a career in NF research. Under this award mechanism, the postdoctoral trainee is considered the Principal Investigator (PI) and, as such, should write the project narrative with appropriate direction from the mentor. The focus of these awards is on the PI, the mentor, and the training program and environment. These awards primarily provide salary support for the PI and require the active involvement of a designated mentor who is an established NF researcher, as evidenced by a demonstrated record of funding and publications. While the PI is not required to have previous experience in NF research, applications for this award must focus on NF research. The FY10 NFRP encourages applications that specifically address the critical needs of the NF community in the following areas: 1) Complications of NF with high mortality such as neoplasms and cerebrovascular abnormalities; 2) Complications of NF with high morbidity such as skeletal maladies, learning deficits, hormone-associated effects, and pain; 3) Refinement and standardization of imaging techniques, molecular and cellular markers, and quality of life metrics for use in future clinical trials; and 4) Translational research such as the development or preclinical testing of therapeutic agents for the treatment of NF. Total Funding: $600K. Eligibility: All. Pre-Application Due Date: April 29, 2010. Closing Date: May 20, 2010.
Posted Date: March 2, 2010
Funding Opportunity Number: W81XWH-10-NFRP-PTA
————————————————————————————–
Neurofibromatosis Exploration – Hypothesis Development Award – The EHDA supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the neurofibromatosis and/or Schwannomatosis research fields. Results of studies conducted through this award may provide the scientific rationale upon which a new hypothesis can be based, or they should provide initial principles of an innovative hypothesis. This award is designed to provide investigators with the opportunity to pursue serendipitous observations. The FY10 NFRP encourages research proposals that specifically address the critical needs of the NF community in the following areas: 1) Complications of NF with high mortality such as neoplasms and cerebrovascular abnormalities; 2) Complications of NF with high morbidity such as skeletal maladies, learning deficits, hormone-associated effects, and pain; 3) Refinement and standardization of imaging techniques, molecular and cellular markers, and quality of life metrics for use in future clinical trials; and 4) Translational research such as the development or preclinical testing of therapeutic agents for the treatment of NF. Total Funding: $725K. Eligibility: All. Pre-Application Due Date: April 29, 2010. Closing Date: May 20, 2010.
Posted Date: March 2, 2010
Funding Opportunity Number: W81XWH-10-NFRP-EHDA
————————————————————————————–
Neurofibromatosis New Investigator Award – The intent of the NFRP NIA is to support the career transition and/or continued development of promising independent investigators in the field of neurofibromatosis research. Experience in NF research is allowed, but not required. However, Principal Investigators (PIs) with a limited background in NF research are strongly encouraged to have a collaborator who is experienced in the NF field. NIA proposals must include preliminary data originating from the PI, research team, or collaborator that is relevant to NF and the proposed project. The FY10 NFRP encourages research proposals that specifically address the critical needs of the NF community in the following areas: 1) Complications of NF with high mortality such as neoplasms and cerebrovascular abnormalities; 2) Complications of NF with high morbidity such as skeletal maladies, learning deficits, hormone-associated effects, and pain; 3) Refinement and standardization of imaging techniques, molecular and cellular markers, and quality of life metrics for use in future clinical trials; and 4) Translational research such as the development or preclinical testing of therapeutic agents for the treatment of NF. Research involving human subject use is permitted; however, clinical trials are not allowed under this funding opportunity. PIs wishing to apply for funding for a clinical trial should utilize the FY10 NFRP Clinical Trial Award mechanism. Total Funding: $1.8M. Eligibility: All. Pre-Application Due Date: April 29, 2010. Closing Date: May 20, 2010.
Posted Date: March 2, 2010
Funding Opportunity Number: W81XWH-10-NFRP-NIA
————————————————————————————–
Tuberous Sclerosis Complex Exploration – Hypothesis Development Award – The EHDA supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in tuberous sclerosis complex research. Results of studies conducted through this award should provide the scientific rationale upon which a new hypothesis can be based, or these results should provide initial principles of an innovative hypothesis. This award is designed to provide investigators with the opportunity to pursue serendipitous observations. The presentation of preliminary data is encouraged, but not required. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate the project’s innovation and the potential impact on TSC. Total Funding: $900K. Eligibility: All. Pre-Application Due Date: April 29, 2010. Closing Date: May 20, 2010.
Posted Date: March 2, 2010
Funding Opportunity Number: W81XWH-10-TSCRP-EHDA
————————————————————————————–
Tuberous Sclerosis Complex Career Transition Award (CARTA) – The CARTA supports TSC researchers during the transition from postdoctoral training to an independent position. This award will cover up to two years of postdoctoral training followed by up to two years of a faculty-level position. Under this award mechanism, the postdoctoral candidate is considered the Principal Investigator (PI). Important aspects of this award are as follows: 1) The award covers the last two years of a postdoctoral fellowship and the first two years of an independent faculty position. 2) Career transition and development plans must be clearly articulated. 3) A mentor must be named who will support and guide the PI during the postdoctoral period of the award. 4) All applications must include preliminary data relevant to TSC research and the proposed project. Clinical trials are not allowed under this award mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Research Award mechanism. Total Funding: $500K. Eligibility: All. Pre-Application Due Date: April 29, 2010. Closing Date: May 20, 2010.
Posted Date: March 2, 2010
Funding Opportunity Number: W81XWH-10-TSCRP-CARTA
————————————————————————————–
Prostate Cancer Population-Based Research Award – The FY10 Population-Based Research Award mechanism supports high-impact, population-based approaches to prostate cancer research. These studies, if successful, should contribute significantly to the elimination of death and suffering from prostate cancer. Proposed research must be responsive to at least one of the FY10 PCRP overarching challenges and at least one of the focus areas. The overall goal of this award is to generate unique information and/or tools that can only be achieved from the perspective of statistical analysis of a defined patient population. Applications may propose retrospective, prospective, case control, cohort, or other population-based study designs, provided the population sample is of sufficient size to demonstrate statistical significance. The study should address a well-developed hypothesis that is conceptually sound and specific for prostate cancer. The statistical expertise of the study team should be clearly described and evident in the study plan. It is expected that investigators will demonstrate appropriate access to the population(s) needed for the study. Research proposed under this award may include the following areas: 1) Biomarkers; 2) Predictors of response to therapy; 3) Disease aggressiveness; 4) Epidemiology; 5) Genomics (germline or somatic); 6) Health disparity; 7) Molecular genetics; 8 ) Risk prediction. Research involving human subject use is permitted under this funding opportunity, but is restricted to studies without clinical trials. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate how the project addresses the following important aspects of the award: 1. Impact: Research that has high impact will, if successful, significantly accelerate the elimination of death and suffering from prostate cancer. 2. Statistical plan: A robust statistical plan is required and should be supported with requisite statistical expertise in the study team. 3. Human subject plan: Applicants should provide documentation demonstrating access to, and ability to recruit, the appropriate population(s) or patient samples in numbers sufficient to achieve statistical significance. 4. Preliminary data: The presentation of preliminary data to support the study feasibility is required. Any preliminary data provided should be from the laboratory of the PI or member(s) of the collaborating team. 5. Responsiveness to PCRP overarching challenges and focus areas: The relevance of the research problem to at least one of the PCRP overarching challenges and at least one of the PCRP focus areas. Total Funding: $2.9M. Eligibility: All. Closing Date: May 26, 2010.
Posted Date: March 2, 2010
Funding Opportunity Number: W81XWH-10-PCRP-PBRA
————————————————————————————–
Prostate Cancer Laboratory-Clinical Transition Award – The goals of the FY10 PCRP are aimed towards eliminating death and suffering from prostate cancer. All applications for the PCRP Laboratory Clinical Transition Award must address at least one of the following PCRP overarching challenges: 1) Develop effective treatments for advanced prostate cancer; 2) Distinguish lethal from indolent disease. Applications for the PCRP Laboratory Clinical Transition Award must also address at least one of the following FY10 PCRP focus areas: a) Biomarkers: Discovery and validation of biomarkers for the detection, prognosis, and progression of prostate cancer; b) Genetics: Understanding the genetics and epigenetics responsible for susceptibility, disease progression, and treatment outcomes for clinically significant prostate cancer; c) Imaging: Development of new imaging technology for the detection and prognosis of prostate cancer, including progression to systemic disease; d) Survivorship: Studies on the impacts of treatment, nutrition, metabolism, and exercise on the well being of prostate cancer patients and their families; e) Therapy: Identification of new targets, pathways, and therapeutic modalities or molecules for the treatment of prostate cancer; f) Tumor Biology: Understanding the heterogeneity and microenvironment for the prognosis and progression of prostate cancer. Total Funding: $2.4M. Eligibility: All. Pre-application Due Date: May 5, 2010. Application Due Date: May 26, 2010.
Posted Date: March 2, 2010
Funding Opportunity Number: W81XWH-10-PCRP-LCTA
————————————————————————————–
Prostate Cancer Health Disparity Research Award – The Health Disparity Research Award supports new ideas that represent innovative approaches to prostate cancer health disparity research with the potential to make an important contribution to eliminating death and suffering from prostate cancer. The Health Disparity Research Award reflects the PCRP’s commitment to resolving disparities in prostate cancer incidence, morbidity, and mortality by funding health disparity-focused projects. Studies proposed for this award mechanism are expected to improve the understanding of, and ultimately eliminate, health disparities. Applicants for this award must explicitly state how the proposed research is related to an area of prostate cancer health disparity. Appropriate health disparity areas include, but are not limited to, race and ethnicity, socioeconomic status, access to health care, insurance status, age, geography, and cultural beliefs.Total Funding: $4.3M. Eligibility: All. Pre-application Due Date: May 5, 2010. Application Due Date: May 26, 2010.
Posted Date: March 2, 2010
Funding Opportunity Number: W81XWH-10-PCRP-HDRA